Gillian McGovern, Associate Editor

The guidelines are believed to promote screening adherence by providing women with a more comfortable, accessible, and less stressful testing option.

Federal vaccine recommendations for pediatric patients shift dramatically, reducing routine immunizations from 17 to 11, sparking debate on safety and efficacy.

The FDA approval of Boncresa and Oziltus, new denosumab biosimilars, enhances access to treatments for osteoporosis and cancer-related bone loss.

New research highlights the efficacy and safety of HRS-1780, an investigational nonsteroidal MRA, in treating chronic kidney disease (CKD).

Research reveals that wildfire smoke exposure significantly impacts pediatric asthma control in the northeastern US, highlighting urgent climate health concerns.

Narsoplimab gains FDA approval for treating transplant-associated thrombotic microangiopathy, showing promising survival rates in high-risk patients.

The FDA's 2025 biosimilar approvals enhanced treatment options for chronic diseases, improving accessibility and affordability for patients and health care providers.

Nufymco, the FDA-approved ranibizumab biosimilar, enhances treatment options for retinal diseases, improving patient access and affordability.

A high-fiber, plant-based diet shows promise in delaying multiple myeloma progression and enhancing metabolism and immune response in patients with precursor conditions.

Researchers uncover how type 2 innate lymphoid (ILC2) and T helper 2 (Th2) cells in allergic asthma survive toxic environments, revealing potential new therapeutic strategies for treatment.

Although both sex groups showed cognitive decline, women with chronic kidney disease (CKD) had significantly better cognitive scores than men.

Research highlights the critical link between chronic kidney disease (CKD) and uncontrolled gout, emphasizing a need for enhanced awareness and treatment strategies.

The approval was supported by findings from the TRITON3 trial, which enrolled certain patients with metastatic castration-resistant prostate cancer (mCRPC).

Findings from a meta-analysis reveal biosimilars for inflammatory bowel disease (IBD) offer similar efficacy and safety and maintained remission rates as their reference products.

The FDA approves depemokimab-ulaa as a long-acting treatment for severe asthma, enhancing patient care with fewer injections and improved outcomes.

FDA grants a national priority voucher to teclistamab and daratumumab for relapsed/refractory multiple myeloma, enhancing treatment approval speed.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

Research reveals that isatuximab on-body injector shows consistent safety and efficacy across various body weight groups in multiple myeloma treatment.

After 2 initial doses, inebilizumab is administered with only 2 doses a year.

A study reveals that many asthma patients switch biologics due to perceived ineffectiveness, highlighting the need for personalized treatment strategies.

Aflibercept biosimilar QL1207 shows comparable efficacy to the reference drug in treating diabetic macular edema, offering a potentially affordable treatment option for those facing adherence and accessibility issues.

FDA approves gepotidacin as a new oral treatment for uncomplicated gonorrhea, expanding options against resistant sexually transmitted infections.

New research highlights the benefits of adding isatuximab to standard therapy for newly diagnosed multiple myeloma (NDMM), improving patient outcomes and quality of life.

The FDA approved etuvetidigene autotemcel, the first gene therapy for Wiskott-Aldrich syndrome, transforming treatment options for affected patients.

Pharmacists leverage sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve interconnected cardiovascular-kidney-metabolic (CKM) syndrome outcomes through holistic, patient-centered care.

The American Cancer Society updates cervical cancer screening guidelines, introducing self-collection options and new exit criteria to enhance accessibility and compliance.

Continuous glucose monitoring (CGM) via interstitial fluid, sweat, and saliva are less invasive than prior methods.

The FDA approves a new dose of Omlyclo, the first interchangeable biosimilar to Xolair, enhancing treatment options for allergic and inflammatory conditions.

The supplemental new drug application (sNDA) was assigned a PDUFA target action date of July 26, 2026.

The blood test helps patients avoid unnecessary and invasive biopsies.